Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment

Affiliations

• ¹ Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark; Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark.
• ² Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK; UCL Institute of Ophthalmology, London, UK; NIHR-Moorfields Biomedical Research Centre, London, UK.
• ³ Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France; Université Paris-Saclay, Versailles-Saint-Quentin-en-Yvelines, Paris, France; Institut de la Vision, Sorbonne Université, Paris, France.
• ⁴ Royal Danish Academy - Architecture, Design, Conservation, Copenhagen, Denmark.
• ⁵ Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France; Institut de la Vision, Sorbonne Université, Paris, France; Faculté de Pharmacie, Paris Cité université, Paris, France.
• ⁶ Department of Ophthalmology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
• ⁷ Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
• ⁸ Department of Ophthalmology, HERA Hospital, Vienna, Austria.
• ⁹ Copenhagen, Denmark.
• ¹⁰ Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany.
• ¹¹ Face Restoration, London, UK.
• ¹² TFOS, Paris, France.
• ¹³ Princess Alexandra Eye Pavilion and Department of Ophthalmology, University of Edinburgh, Edinburgh, UK.
• ¹⁴ Fight for Sight, Copenhagen, Denmark.
• ¹⁵ TFOS, Boston, MA, USA. Electronic address: david@tearfilm.org.